Hinxton Retreat Workshop on Membranoproliferative Glomerulonephritis Type II

描述(由申请人提供)： 第二届膜增生性肾小球肾炎(MPGN II)国际会议将于2006年8月18日至20日在英国剑桥欣克斯顿基因组校园的惠康信托会议和会议中心举行。本次会议的目的和目标是：1)介绍我们对MPGN II分子遗传学的了解进展；2)介绍MPGN II治疗方案的动物试验结果；3)确定和确定当前的研究问题和必须解决的问题，以促进科学知识和刺激研究，从而开发有效的治疗方法来预防MPGN II的进展和复发。这些目的和目标是2004年8月13-14日在波士顿举行的关于MPGN II的第一次国际会议的合乎逻辑的延伸，将通过以下方式实现：1)聚集具有补体介导疾病专业知识的基础科学家、具有肾小球疾病专业知识的肾脏病理学家、具有肾小球肾炎专业知识的临床肾病学家、具有MPGN II专业知识的遗传学家和具有补体级联专业知识的化学家；2)关注导致MPGN II的致病机制，特别强调最近发现的与这种疾病有关的H因子；3)回顾动物数据，探索正在CFH/-小鼠突变体中测试的几种抗补体策略；以及4)重申KIDNEEDS的承诺，该基金是大雪松急流基金会的一个非营利性基金，将继续为MPGN II的研究提供支持。会议将持续两天。第一天将包括关于MPGN II的临床流行病学、肾小球和MPGN II的遗传学的演讲和讨论。第二天将包括集中讨论在治疗MPGN II时应考虑的治疗方案的演讲和讨论。在我们使用圆桌讨论形式的第一次会议取得成功的基础上，我们将在本次会议上使用类似的会议结构。第一次会议的结果清楚地定义了MPGN II的知识状况，发表在《美国肾病学会杂志》(Appl等人，2005年)上。我们还将公布这次会议的记录。这笔赠款是为了支持来自北美的科学家参加将于2006年8月18日至20日在英国剑桥欣克斯顿基因组校园的惠康信托会议和会议中心举行的第二届膜增生性肾小球肾炎(MPGN II)国际会议。

DESCRIPTION (provided by applicant): The second international conference on Membranoproliferative Glomerulonephritis Type II (MPGN II) will be held August 18-20, 2006 at the Wellcome Trust Conference and Meetings Centre on the Genome Campus, Hinxton, Cambridge UK. The aims and objectives of this meeting are: 1) To present advances in our understanding of the molecular genetics of MPGN II; 2) To present results of animal trials focused on therapeutic options for MPGN II; 3) To identify and define current research problems and issues that must be addressed in order to advance scientific knowledge and stimulate research that will lead to the development of effective therapies to prevent progression and recurrence of MPGN II. These aims and objectives are a logical extension of the first international conference on MPGN II held in Boston, MA August 13-14, 2004, and will be achieved by: 1) bringing together basic scientists with expertise in complement-mediated disease, nephro-pathologists with expertise in glomerulopathies, clinical nephrologists with expertise in glomerulonephritis, geneticists with expertise in MPGN II, and chemists with expertise in the complement cascade; 2) focusing on pathogenic mechanisms that lead to MPGN II, with special emphasis on recent discoveries implicating factor H in this disease; 3) reviewing animal data exploring several anti-complement strategies that are being tested in the Cfh -/- mouse mutant; and, 4) reaffirming the commitment of KIDNEEDS, a not-for-profit fund of the Greater Cedar Rapids Foundation, Cedar Rapids, IA to provide continued support for MPGN II research. The conference will span two days. The first day will include talks and discussions focused on the clinical epidemiology of MPGN II, the glomerulus, and the genetics of MPGN II. The second day will include talks and discussions focused on therapeutic options that should be considered in the treatment of MPGN II. Building on the success of the first conference in which we used a round-table discussion format, we will use a similar conference structure at this meeting. The outcome of first conference clearly defined the state of knowledge of MPGN II as published in the Journal of the American Society of Nephrology (Appel et al., 2005). We will also publish the proceedings of this meeting. This grant is to support scientists from North America attending the 2nd international conference on Membranoproliferative Glomerulonephritis Type II (MPGN II) to be held August 18-20, 2006 at the Wellcome Trust Conference and Meetings Centre on the Genome Campus, Hinxton, Cambridge UK.